Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841257 | 0.86 | CASP3 (0.50) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2533142 | 0.81 | CASP3 (0.51) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1838470 | 0.81 | CASP3 (0.45) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2540722 | 0.78 | MET (0.52) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2539011 | 0.78 | NPC1 (0.42) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2536661 | 0.78 | NPC1 (0.49) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2541319 | 0.76 | MET (0.46) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2530711 | 0.76 | MET (0.61) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2534423 | 0.74 | MET (0.49) | ABL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2538170 | 0.74 | PIK3CA (0.49) | NPC1RAB9ASMN1; SMN2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | claimed |
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | ABL1 7/4885NPC1 1726/4885RAB9A 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.